Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00738621 · ClinicalTrials.gov registry record · Phase 4

Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients

A Phase 4 study of Postoperative Nausea and Vomiting, sponsored by Scott and White Hospital & Clinic.

Completed
Registry status
Phase 4
Development phase
100
Enrollment target
1
Study location

NCT00738621 is a Phase 4 study of Postoperative Nausea and Vomiting that has completed, run by Scott and White Hospital & Clinic. The registered enrollment target is 100 participants, below the 460-participant average among 9 other Postoperative Nausea and Vomiting trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00738621, a Phase 4 study of Postoperative Nausea and Vomiting, has completed, sponsored by Scott and White Hospital & Clinic.

COMPLETED
Registry status
Phase 4
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare the efficacy of the use of oral aprepitant in combination with intravenous ondansetron and dexamethasone with the efficacy provided by the use of oral aprepitant and dexamethasone for preventing vomiting during the first 24-48 hours after breast surgery.

Interventions

  • DRUG Aprepitant, Dexamethasone, Ondansetron
  • DRUG Aprepitant, Dexamethasone, Placebo

Study Locations (1)

Texas

  • Scott and White Healthcare - Temple

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2008-07
Est. Completion 2010-08
Phase Phase 4

What the Registry Record Tells You About NCT00738621

The ClinicalTrials.gov registry entry for NCT00738621 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 460-participant average among 9 other Postoperative Nausea and Vomiting trials with a reported enrollment target (78% lower). The listed sponsor is Scott and White Hospital & Clinic, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Postoperative Nausea and Vomiting appearing as the primary indexed condition, and to 2 interventions - of which Aprepitant, Dexamethasone, Ondansetron is the first listed.

NCT00738621 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00738621 about?

NCT00738621 is a clinical study titled "Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients". The purpose of this study is to compare the efficacy of the use of oral aprepitant in combination with intravenous ondansetron and dexamethasone with the efficacy provided by the use of oral aprepitant and dexamethasone for preventing vomiting during the first 24-48 hours after breast surgery.

What is the current status of trial NCT00738621?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2008-07. Estimated completion is 2010-08.

What conditions does trial NCT00738621 study?

This clinical trial studies the following conditions: Postoperative Nausea and Vomiting.

What interventions are being tested in trial NCT00738621?

The interventions under investigation include: Aprepitant, Dexamethasone, Ondansetron (DRUG), Aprepitant, Dexamethasone, Placebo (DRUG).

Who is sponsoring clinical trial NCT00738621?

This trial is sponsored by Scott and White Hospital & Clinic, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00738621 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Postoperative Nausea and Vomiting

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.